Post-Marketing Surveillance of Adverse Events Following Immunization with <i>Haemophilus Influenzae</i> Type b Conjugate Vaccine — China, 2010

Post-Marketing Surveillance of Adverse Events Following Immunization with <i>Haemophilus Influenzae</i> Type b Conjugate Vaccine — China, 2010–2021

Published:2024 Issue:33 Volume:6 Page:834-840
ISSN:2097-3101
Container-title:China CDC Weekly
language:en
Short-container-title:

Author:

Ren Minrui, ,Li Keli,Li Yan,Fan Chunxiang,Xu Yuyang,Zhang Lina,Li Yuan,Cao Lei,Yu Wenzhou,Yin Zundong,

Publisher

Chinese Center for Disease Control and Prevention

Link

https://weekly.chinacdc.cn/en/article/pdf/preview/10.46234/ccdcw2024.180

Reference15 articles.

1. World Health Organization. WHO position papers on Haemophilus influenzae type b. 2022. https://www.who.int/teams/immunization-vaccines-and-biologicals/policies/position-papers/haemophilus-influenzae-type-b. [2024-2-2].

2. Ministry of Health of China, State Food and Drug Administration of China. National guideline for the surveillance of adverse events following immunization (AEFI). 2010. http://www.nhc.gov.cn/jkj/s3581/201402/5dd5633d93174a7c8e93d8af7579a613.shtml. [2023-1-10]. (In Chinese).

3. Ministry of Health of China. Identification of adverse reaction after immunization. 2018. http://www.nhc.gov.cn/fzs/s3576/201808/e4f7a5704a994a14bd28cd82f94d27e2.shtml. [2023-1-10]. (In Chinese).

4. Zhang LN, Li KL, Li Y, Fan CX, Li Y, Ren MR, et al. Surveillance of adverse events following immunization in China, 2020. Chin J Vaccines Immun 2022;28(2):208 − 18 https://doi.org/10.19914/j.CJVI.2022041. (in Chinese).

5. Li ZQ, Xu JX, Tan HF, Zhang CH, Chen J, Ni LH, et al. Safety of pentavalent DTaP-IPV/Hib combination vaccine in post-marketing surveillance in Guangzhou, China, from 2011 to 2017. Int J Infect Dis 2020;99:149 − 55. https://doi.org/10.1016/j.ijid.2020.07.019.